Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06754644 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Not Yet Recruiting to Recruiting Enrollment target: 464 to 808 · Study sites: 0 to 1 · Start date changed from estimate of Jan 2025 to Jan 15, 2025v2 Show 3 more changesShow less
    • Enrollment target: 464 to 808
    • Study sites: 0 to 1
    • Start date changed from estimate of Jan 2025 to Jan 15, 2025
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is to compare the efficacy similarities between QL2107 and Keytruda in metastatic non-squamous NSCLC.
Trial Details
NCT Number NCT06754644
Lead Sponsor Qilu Pharmaceutical Co., Ltd.
Conditions NSCLC
Enrollment 808 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov